55 results about "Reduced serum uric acid" patented technology

The present invention provides a composition comprising at least one microorganism selected from the group consisting of lactic acid bacteria and yeasts that have an ability to decompose purines and an action of lowering serum uric acid level and in particular, such a composition in a food, beverage or pharmaceutical form. Such a composition is effective in the prevention and amelioration of hyperuricemia.

Provided is a method for obtaining a lactic acid bacterium having a property of reducing a serum uric acid level. The present invention relates to: a method for screening for a lactic acid bacterium, which comprises determining the amount of a purine body incorporated in each of lactic acid bacteria in a culture medium containing the purine body and then screening for a lactic acid bacterium having a property of trapping the purine body among the lactic acid bacteria employing the amount as a measure; and a purine body trapping agent for reducing a serum uric acid level, which comprises a lactic acid bacterium obtained by the method.

Provided herein are methods of treating gout, treating hyperuricemia, lowering serum uric acid, or the like with compounds of formula (I) have the following structure Further, provided herein are compositions comprising a compound of formula (I).

The present invention relates to a celery seed extract, a preparation and a preparation method thereof. The preparation method comprises: taking dried celery seeds, and carrying out reflux extraction 1-2 times with 2-4 times the volume of an ethanol aqueous solution with a volume fraction of 95%; collecting the extraction liquids, and carrying out pressure reducing concentration to obtain a thick extract; suspending the thick extract in water having the volume 0.5-1 time the volume of the raw material, extracting 2-4 times with an extraction reagent, and combining the organic phases after completing the extracting to obtain a crude extract; weighing silica gel having the mass of 35-55 times the mass of the crude extract, activating for 1 h at a temperature of 130 DEG C, and loading into a chromatography column; taking the crude extract, and injecting in a concentration of 0.2-0.5 g / ml; and carrying out gradient elution with petroleum ether-dichloromethane-ethyl acetate, collecting the flow, and carrying out pressure reducing concentration to obtain the celery seed extract. According to the present invention, the preparation method has characteristics of simple preparation process, less extraction number, and high yield; and the obtained celery seed extract has the good serum uric acid lowering effect.

The invention provides combined application of nuciferine and analogue thereof and a drug. The drug is used for treating or preventing hyperuricemia and reducing the serum uric acid level.

The invention belongs to the Chinese medicine field, in particular to a Chinese medicine for treating gout disease; the invention is characterized in that the proportion of the raw herbal materials of the invention by weight is: 15-20 parts of Chinese atractylodes, 15-18 parts of phellodendron, 15-20 parts of twotooth achyranthes root, 10-13 parts of akebiaquinata, 6-10 parts of Indian Buead peel, 8-12 parts of fourstamen stephania root, 9-13 parts of cortex lycii radicis, 10-18 parts of alismatis, 18-32 parts of semen plantaginis, and 3-8 parts of crocodile bones. The product of the invention has the functions of clearing heat, eliminating dampness, activating blood circulation, removing stagnated blood, inducing diuresis for removing edema, tonifying the kidney and nourishing the liver and removing bruise for relieving pain, can reduce serum uric acid, treat gouty arthritis, prevent the deformity caused by arthritis and prevent renal lesions, prevent urate calculi and gout calculi from being formed, and so on; thus the suffering of patients can be relieved.

The invention provides functional beverage containing spirulina and skipjack bone extractive. The preparation method of the beverage comprises the steps of mixing spirulina and skipjack bone extractive, performing enzymolysis to the mixture through bromelain, coating enzymatic hydrolysate through beta-cyclodextrin, and then adding other adjuvant, so as to form the beverage. The beverage not only removes algae fishy smell of spirulina, has good mouthfeel and is easy to absorb, but also can effectively reduce the serum urate level, and is small in untoward effect.

The invention provides an application of Erding granules in preparation of drugs for treating or preventing hyperuricemia and gout diseases. Provided evidences indicate that the Erding granules have new application of obviously preventing and treating hyperuricemia and gout diseases. The Erding granules are disclosed to have obvious hypouricemic effect, so as to reduce serum uric acid values of hyperuricemia and gout diseases and alleviate clinical symptoms of patients with gout.

A composition for treating or preventing hyperuricemia which contains a chondroitin sulfate protein complex as an effective ingredient. Because of having an effect of lowering serum uric acid level, this composition makes it possible to provide a novel method of the treatment, the prevention and the relief of gout.

The invention discloses an application of elaeagnus conferta roxb, namely the application of the elaeagnus conferta roxb in preparation of drugs for treating kidney stones, gall-stone and hyperuricemia. In the treatment of the kidney stones, the drug is used for reducing the rate of the kidney stones, improving kidney coefficient, reducing calcium content of the kidney, reducing serum urea nitrogen and reducing serum creatinine. In the treatment of the gall-stone, the elaeagnus conferta roxb is used for treating bile pigment gallstones and cholesterol gallstones; preferably in the treatment of bilirubin gallstones, the elaeagnus conferta roxb is used for reducing the rate of the gallbladder stones, calcium ion content in bile, total bilirubin concentration and free bilirubin concentration in the treatment of the bile pigment gallstones; in the treatment of the cholesterol gallstones, the elaeagnus conferta roxb is used for reducing the rate of the gallbladder stones and the cholesterol content in the bile; and in the treatment of hyperuricemia, the elaeagnus conferta roxb is used for reducing uric acid content in serum. The application of the elaeagnus conferta roxb can be spread to related products of the elaeagnus conferta roxb; and the related product includes a fruit aqueous extract of the elaeagnus conferta roxb, dewatered elaeagnus conferta roxb, capsules, troches, granulas, fruit vinegar, jam and fruit juice.

The invention relates to a preparation method and an application of kelp extract for effectively reducing uric acid, and belongs to the technical field of biological medicines. The preparation method particularly includes the steps: soaking dried kelps in 4 DEG C distilled water for 24-36 hours; draining and shearing the kelps; adding ethyl alcohol according to the mass-volume ratio of 1:6-10; sufficiently homogenizing the ethyl alcohol; stirring and soaking the kelps at the temperature of 4 DEG C for 48-72 hours after ultrasonic treatment; pumping filter liquor to 1 / 3 volume in vacuum; performing ultra-filtration concentration and vacuum freeze-drying to obtain the uric acid reducing kelp extract. By the aid of the kelp extract, the expression level of urate decorporation genes UAT can be remarkably improved, the expression level of urate reabsorption genes URAT can be reduced, and the content of serum uric acid is remarkably reduced on the premise of protecting renal functions.

A composition for treating or preventing hyperuricemia which contains a chondroitin sulfate protein complex as an effective ingredient. Because of having an effect of lowering serum uric acid level, this composition makes it possible to provide a novel method of the treatment, the prevention and the relief of gout.

The invention discloses a teabag for preventing and treating gout. The teabag is prepared through the following raw materials in parts by weight: 6-12 parts of astragalus membranaceus, 6-12 parts of pueraria lobate, 6-12 parts of gynostemma pentaphylla, 4-10 parts of poria cocos, 1-5 parts of pseudo-ginseng, 0.5-2 parts of cordyceps militaris, and 2-8 parts of green tea. The teabag is capable of promoting urate excretion, reducing serum uric acid level, and preventing and treating gout, and is fast to take effect; gout is not liable to reoccur.

The invention discloses a uric acid lowering oral enteric-coated preparation. The uric acid lowering oral enteric-coated preparation is characterized by containing uricase, alkalescent additives and uricase protecting agent, wherein the uricase is recombinant uricase, macromolecular bacteria extract containing uricase or macromolecular fungus extract containing uricase; the alkalescent additives are an alkalescent mixture prepared from sodium bicarbonate, sodium phosphates, sodium acetate and other medical salts of organic weak acids and inorganic weak acids; the uricase protecting agent is edible protein powder, which is rich in protein content and free from obvious proteinase activity or even denatured. The uric acid lowering oral enteric-coated preparation degrades uric acid in intestines to reduce the serum uric acid level and takes effects without reliance on absorption, thereby avoiding liver and kidney toxicity, adverse cardiovascular response or other post-absorption adverse response led by traditional uric acid lowering medicines and further being applicable to prevention of hypeluricemia and gout.

Problem: Providing a composition with an action of decreasing uric acid level in human sera from a residue from distillation of distilled spirits from barley as a material having been disposed so far despite no safety problem, by a simple treatment method suitable for practical industrial-scale production without any complex purification step.Means for Solving the Problem: A serum uric acid level-decreasing agent containing as the active ingredient a component from barley subjected to fermentation, preferably a residue from distillation of distilled spirits from barley, or a liquid fraction (residual solution from distillation of distilled spirits from barley) obtained by subjecting the residue from distillation of distilled spirits from barley to a separation procedure to a solid fraction and the liquid fraction, and / or a composition obtained by fractionating the residual solution from distillation of distilled spirits from barley, which is preferably a pharmaceutical agent for the prophylaxis or therapeutic treatment of diseases requiring the decrease of serum uric acid level. A composition containing the serum uric acid level-decreasing agent is in a form of foods and drinks, pharmaceutical products and quasi-pharmaceutical products, or feeds. Foods and drinks with a label telling that the foods and the drinks are used for the prophylaxis of diseases requiring the decrease of serum uric acid level, preferably functional foods and drinks, foods and drinks as nutritious supplements or healthy foods and drinks, for decreasing serum uric acid level.

The invention which belongs to the field of traditional Chinese medicines discloses a medicine for reducing serum uric acid, a preparation method thereof and a purpose thereof. The medicine is prepared from the following medicinal materials, by weight, 5-15 parts of edible tulip bulb, 10-60 parts of Smilax glabra, 6-30 parts of parasitic loranthus, 9-45 parts of Radix Astragali, 10-30 parts of Savia miltiorrhiza, 10-60 parts of coix seed, and 9-20 parts of Gentiana macrophylla. The medicinal materials are subjected to technologies of decoction, concentration, impurity removal, drying and the like to obtain effective parts for reducing serum uric acid, and the effective parts can be prepared into different clinically acceptable dosage forms with routine methods. The purpose comprises applications in preparing medicines for reducing serum uric acid, blood fat and protecting livers and kidneys, and applications of medicines for treating hyperuricacidemia or concurrent hyperuricacidemia. The medicine of the present invention which has effects of reducing serum uric acid, blood fat and protecting livers and kidneys can be used for treating hyperuricacidemia or concurrent hyperuricacidemia.

The invention provides a pharmaceutical composition for the treatment of hyperuricemia which is prepared from, by weight, 4-6 parts of radix fici simplicissimae, 2-3 parts of phellinus igniarius and 2-3 parts of folium microcotis. The invention further provides a preparation method of the pharmaceutical composiiton. In the composition, the radix fici simplicissimae, phellinus igniarius and foliummicrocotis are taken as crude drugs and have synergistic effect at a specific ratio, and good effect of reducing blood uric acid can be produced; the efficacy test shows that the pharmaceutical composition can reduce the blood uric acid and inhibit serum xanthine oxidase activity remarkably and a new selection is provided for clinical use of drugs to reduce serum uric acid and treating hyperuricemia.

The invention relates to the field of pharmaceutical chemistry, and discloses mangiferin aglycone crystal forms I and II, and a pharmaceutical composition, preparation method and application thereof. The mangiferin aglycone crystal form I or crystal form II provided by the invention has the advantages of single crystal form, high purity, high stability, high solubility and high bioavailability, can lower the serum uric acid concentration, and can be used for preparing medicines for preventing and treating hyperuricemia. The preparation method of the mangiferin aglycone crystal form I or crystal form II has the advantages of accessible raw materials and low production cost, and is suitable for industrial production.

The invention relates to application of a compound in preparation of a drug for treating gout. The compound has a structure as shown in formula I. Through experiments, it shows that the compound can inhibit URAT1, reabsorption of uric acid is stopped, discharge of the uric acid of rats can be promoted, the serum urate levels is reduced, sodium urate induced THP-1 CELL IL-1 beta and TNF-alpha secretion can further be inhibited obviously, the degree of rat ankle swelling caused by sodium urate is reduced, inflammatory response is reduced, and arthralgia is relieved. It shows that the compound has effect of treating hyperuricemia and / or gout and has high application value.

A method for treating gout and / or reducing serum uric acid levels in a patient is disclosed that includes administering to the patient a therapeutically effective amount of an amine polymer, for example, an aliphatic amine polymer. In one embodiment, the polymer binds to uric acid or a precursor thereof. Examples of polymers useful in an embodiment of the invention include sevelamer hydrochloride and colesevelam. The invention includes the use of amine polymers such as a cross-linked polymer characterized by a repeat unit having the formula:and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4. Also described is a use, for the manufacture of a medicament, of a polymer that binds serum uric acid in a patient.

The invention belongs to the technical field of health care products, and particularly relates to a potassium citrate effervescent tablet composition capable of lowering a uric acid. The composition comprises a composition capable of lowering the uric acid, maltooligosaccharide, sodium citrate, sodium chloride, magnesium carbonate, potassium citrate, calcium lactate, vitamin B1, vitamin B2, ascorbic acid, tartaric acid, sodium bicarbonate, L-arginine, taurine and green tea extracts. After mangoes, hovenia acerba lindl., cherries and a wine are mixed to obtain a fruit wine, the fruit wine is added into raw materials for preparing the effervescent tablet, and the effervescent tablet capable of replenishing physical abilities can supplement enough nutrient substances, including electrolytes,sodium chlorides, vitamins and the like, which are required for organisms to the organisms so as to maintain the acid-base balance of a human body. Tonifying food materials, including mangoes, hoveniaacerba lindl., cherries and the like, in the fruit wine neutralize excessive acidic substances in the organisms, the activity of purine oxidase is inhibited, the generation of the uric acid is reduced, the acid-base balance of the organism is regulated, uric acid excretion is accelerated, and the level of the serum uric acid is lowered.

The invention relates to a tuna oligopeptide powder composition. The tuna oligopeptide powder composition comprises the following components in parts by weight: 25-30 parts of tuna oligopeptide powder, 10-15 parts of fructo-oligosaccharide, 15-20 parts of fish collagen peptide powder, 15-20 parts of Western Indian cherry juice powder and 15-20 parts of honey peach juice powder. 5-10 parts of erythritol, 1-2 parts of a compound sour sweetening agent and 3-4 parts of water-soluble sugar, wherein the water-soluble sugar is fucoidin or chitosan oligosaccharide. The tuna oligopeptide powder composition is used for reducing the uric acid level in serum. The tuna oligopeptide powder composition not only can effectively reduce the serum uric acid level, but also can effectively reduce the serum uric acid level, the main component small molecule peptide is easily absorbed by the human body, the compatibility of various raw and auxiliary materials is helpful for maintaining the health level, notoxic or side effect is caused after long-term eating, the defect of side effects of drugs can be effectively solved, and the human health condition is maintained.

The invention discloses a broiler chicken low-protein feed suitable for heat stress and application of the broiler chicken low-protein feed, and belongs to the field of animal husbandry and feed. Thecrude protein content in the feed can be reduced by 4-4.5% compared with the feeding standard, the feed is prepared on the basis of an ideal amino acid mode, and cystine, glycine and other crystallineamino acids are added. The broiler chicken low-protein feed can overcome the defect of poor broiler chicken feeding effect of low-protein daily ration in summer heat stress ubiquitous in the industry. Under a heat stress condition, after broiler chickens are fed with the feed, the weight gain can be remarkably improved, the feed efficiency can be improved, the pectoral muscle rate can be increased, and the serum uric acid level can be reduced. The feed not only can save protein feed and improve the utilization rate of nitrogen, but also can ensure that the broiler chickens can obtain the growth performance and carcass composition which are equal to or superior to those of a normal feed, and has remarkable ecological benefits and good application prospects.

The invention belongs to the field of medicinal chemistry, and relates to an application of oridonin in preparation of drugs for treating hyperuricemia and resisting gout. The invention provides a newapplication of oridonin as a unique effective component or a main effective component in preparation of drugs for treating hyperuricemia and resisting gout. The application amount of oridonin in miceis intragastric administration according to 10 mg / kg body weight, and oridonin can reduce the serum uric acid level after administration, inhibits the xanthine oxidase activity in liver tissues, produces the effects of treating hyperuricemia and resisting gout, and has the advantages of small dosage, no obvious toxicity to liver and kidney, and the like. The invention opens up a new application of oridonin, and provides a new direction for improving the phenomenon of large side effects of existing drugs for resisting gout.

The invention provides an application of olsalazine sodium in preparation of medicines for preventing and treating hyperuricemia and gout. The olsalazine sodium obviously inhibits the activity of xanthine oxidase in vitro, has IC50 of 9.8mu mol / L, and is a hybrid type xanthine oxidase inhibitor. The in vivo study shows that intraperitoneal injection of the 5.0mg / kg compound obviously reduces the level of serum uric acid of an oteracil potassium induced hyperuricemia mouse, and the dosage for reducing serum uric acid is very less than the dosage for treating ulcerative colitis clinically; and the olsalazine sodium has the characteristics of high efficiency and low toxicity and can be used for preparing medicines and health products for preventing and treating hyperuricemia and gout.

The invention relates to the field of medicinal chemistry and discloses crystal forms I and II of mangiferin aglycon and pharmaceutical compositions, preparation methods and application of the crystal forms I and II. The crystal form I or II of mangiferin aglycon disclosed by the invention is single, high in purity, high in stability and high in solubility and bioavailability, is capable of reducing the concentration of a serum uric acid, and can be used for preparing drugs for preventing and treating hyperuricemia. The preparation method for the crystal form I or II of mangiferin aglycon disclosed by the invention is simple to operate, is easy to obtain raw materials, are low in production cost and is suitable for industrial production.

The invention discloses application of centipede and pseudo-ginseng extract in preparation of a medicine for treating gout and a pharmaceutical composition of the centipede pseudo-ginseng extract. The centipede pseudo-ginseng extract contains centipede and pseudo-ginseng total saponin and is prepared by adopting a water decocting method. Pharmacological testing and clinical test prove that the centipede and pseudo-ginseng extract has a good effect for treating gout and has the advantages of high efficiency and low toxicity. The centipede and pseudo-ginseng extract has the effect of reducing serum uric acid level in a rat suffering from hyperuricemia, and the treatment effect is played without adopting the means of inhibiting expression of xanthine oxidase. The centipede and pseudo-ginseng extract has the effect of reducing the serum uric acid level in a mouse suffering from hyperuricemia.